Following recent concern that the hypoglycemic agent rosiglitazone might increase the already elevated risk of myocardial infarction in patients with type 2 diabetes, Home et al. conducted an ...

A trial in which rosiglitazone and glipizide were compared supports earlier findings that rosiglitazone does not have an adverse effect on the progression of coronary atherosclerosis ...

Objective: Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these previous studies were either ...